QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:VLON

Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free VLON Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.51
▼
$0.53
50-Day Range
$0.27
▼
$2.87
52-Week Range
$0.21
▼
$12.92
Volume
45,867 shs
Average Volume
5.78 million shs
Market Capitalization
$6.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsInsider TradesSocial Media
VLON stock logo

About Vallon Pharmaceuticals Stock (NASDAQ:VLON)

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

VLON Stock News Headlines

July 21, 2023 | forbes.com
Questcor Pharmaceuticals,
April 20, 2023 | bizjournals.com
Vallon Pharmaceuticals' shareholders approve reverse merger with California company
April 19, 2024 | Behind the Markets (Ad)
Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
April 20, 2023 | finance.yahoo.com
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split
April 12, 2023 | finance.yahoo.com
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
April 7, 2023 | bizjournals.com
Lab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for merger
April 4, 2023 | finance.yahoo.com
Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET
February 24, 2023 | finanznachrichten.de
Vallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
April 19, 2024 | Behind the Markets (Ad)
Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
February 24, 2023 | finance.yahoo.com
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
February 14, 2023 | benzinga.com
Is Vallon Pharmaceuticals Inc (VLON) recent surge justified
January 11, 2023 | finance.yahoo.com
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
December 27, 2022 | benzinga.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLON
December 14, 2022 | bizjournals.com
Vallon Pharmaceuticals to merge with California biotech firm in 'best path forward'
December 14, 2022 | msn.com
What's Going On With Vallon Pharmaceuticals Stock Today?
December 14, 2022 | benzinga.com
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
December 13, 2022 | finance.yahoo.com
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
November 3, 2022 | finance.yahoo.com
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
July 28, 2022 | finance.yahoo.com
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 20, 2022 | finance.yahoo.com
Vallon Pharmaceuticals, Inc. (VLON)
May 16, 2022 | bizjournals.com
Vallon Pharmaceuticals plans $3.9M stock sale to support exploration of strategic alternatives
May 13, 2022 | seekingalpha.com
Vallon Pharmaceuticals to raise $3.9M in stock offering
May 13, 2022 | finance.yahoo.com
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
May 12, 2022 | finance.yahoo.com
Vallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS Stimulant
May 12, 2022 | finance.yahoo.com
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 11, 2022 | finance.yahoo.com
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
May 9, 2022 | finance.yahoo.com
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
See More Headlines
Receive VLON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VLON
CUSIP
N/A
CIK
1824293
Web
www.vallon-pharma.com
Phone
267-607-8255
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,020,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-230.48%
Return on Assets
-124.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.29
Quick Ratio
2.29

Sales & Book Value

Annual Sales
$100,000.00
Price / Sales
69.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.18 per share
Price / Book
2.87

Miscellaneous

Outstanding Shares
13,482,000
Free Float
8,453,000
Market Cap
$6.98 million
Optionable
Not Optionable
Beta
-1.14
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

VLON Stock Analysis - Frequently Asked Questions

When did Vallon Pharmaceuticals' stock split?

Shares of Vallon Pharmaceuticals reverse split on Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Vallon Pharmaceuticals IPO?

Vallon Pharmaceuticals (VLON) raised $15 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,700,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

This page (NASDAQ:VLON) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative